EGFR and esophageal squamous cell carcinoma: To identify mediators of resistance to EGFR inhibition, the intrinsic gefitinib sensitivity of a panel of 13 well-characterised ESCC cell lines was determined by dose-response viability screens (Fig. 1a, b).